Nightfood Holdings (OTCQB: NGTF), through its TechForce Robotics subsidiary, announced the advancement of Phase 2 objectives under its joint development collaboration with Oncotelic Therapeutics (OTCQB: OTLC), highlighted by the deployment of PUR-E, an autonomous clean room support robot, within SAPU Bio’s OEB-5 sterile injectable cGMP facility. The deployment expands the initiative beyond Phase 1 materials logistics operations and into sterile manufacturing and clean room environments, where TechForce and Oncotelic are evaluating robotics, automation and AI-driven technologies to support regulated pharmaceutical workflows.
PUR-E joins TechForce’s LIM-E autonomous GMP support robot at the SAPU Bio facility, where the systems are being used to assess opportunities in sterile manufacturing operations, electronic batch record processes and other cGMP activities. According to the companies, the initiative is part of a broader effort to develop robotics and automation solutions for pharmaceutical manufacturing, biotechnology and life sciences environments, with PUR-E operating as part of TechForce’s Robotics-as-a-Service Provider (RaaSP) platform.
NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://nnw.fm/NGTF
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer